Cargando…

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials

Objective To evaluate the benefits and harms of low dose aspirin in people with diabetes and no cardiovascular disease. Design Meta-analysis of randomised controlled trials. Data sources Medline (1966-November 2008), the Cochrane central register of controlled trials (Cochrane Library 2008;issue 4),...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Berardis, Giorgia, Sacco, Michele, Strippoli, Giovanni F M, Pellegrini, Fabio, Graziano, Giusi, Tognoni, Gianni, Nicolucci, Antonio
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2774388/ https://www.ncbi.nlm.nih.gov/pubmed/19897665 http://dx.doi.org/10.1136/bmj.b4531

Ejemplares similares

Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins
por: De Berardis, Giorgia, et al.
Publicado: (2007)

Statins but Not Aspirin Reduce Thrombotic Risk Assessed by Thrombin Generation in Diabetic Patients without Cardiovascular Events: The RATIONAL Trial
por: Macchia, Alejandro, et al.
Publicado: (2012)

The Drug Derived Complexity Index (DDCI) Predicts Mortality, Unplanned Hospitalization and Hospital Readmissions at the Population Level
por: Robusto, Fabio, et al.
Publicado: (2016)

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
Publicado: (2010)

Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events
por: Sylvester, Katelyn W, et al.
Publicado: (2013)

Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events
por: Djatche, Laurence M., et al.
Publicado: (2018)

Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
por: Franciosi, Monica, et al.
Publicado: (2013)

Which people should take aspirin for primary prevention of cardiovascular disease?
por: Lozano, Roberto, et al.
Publicado: (2015)

Aspirin for Prevention of Cardiovascular Disease
por: Mendy, Vincent L., et al.
Publicado: (2017)

Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial
por: Saglimbene, Valeria, et al.
Publicado: (2017)

Cardiovascular Prevention in People Living With HIV: Is There a Rationale to Move Beyond Aspirin?
por: Silvain, Johanne, et al.
Publicado: (2022)

Aspirin for primary prevention of cardiovascular disease
por: Nansseu, Jobert Richie N., et al.
Publicado: (2015)

Aspirin for Primary Prevention of Cardiovascular Disease
por: Kim, Ji Hye, et al.
Publicado: (2019)

Pros and Cons of Aspirin Prophylaxis for Prevention of Cardiovascular Events in Kidney Transplantation and Review of Evidence
por: Khalil, Muhammad Abdul Mabood, et al.
Publicado: (2019)

Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018
por: Christensen, Mikkel B., et al.
Publicado: (2021)

Quality of Diabetes Care Predicts the Development of Cardiovascular Events: Results of the AMD-QUASAR Study
por: Rossi, Maria C.E., et al.
Publicado: (2011)

Aspirin overutilization for the primary prevention of cardiovascular disease
por: VanWormer, Jeffrey J, et al.
Publicado: (2014)

Aspirin for primary prevention of cardiovascular disease in diabetes
por: Xing, Ying, et al.
Publicado: (2019)

Aspirin for the primary prevention of cardiovascular disease in the elderly
por: O’Sullivan, Jack W
Publicado: (2019)

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
por: Coccheri, Sergio
Publicado: (2017)

Aspirin in the Modern Era of Cardiovascular Disease Prevention
por: Murphy, Ella, et al.
Publicado: (2021)

Aspirin in primary prevention of cardiovascular disease in diabetes
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2021)

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
por: Schirosi, Laura, et al.
Publicado: (2016)

Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
por: Petersohn, Svenja, et al.
Publicado: (2020)

Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis
por: Zhao, Binghao, et al.
Publicado: (2021)

Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease
por: Dai, Yuxiang, et al.
Publicado: (2012)

Use of Aspirin and Statin as primary prevention for cardiovascular diseases
por: Alkhail, Bahaa Aba, et al.
Publicado: (2016)

Aspirin use for cardiovascular disease prevention in the uninsured population
por: Liu, Nina, et al.
Publicado: (2020)

Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19
por: Diaz, Temistocles, et al.
Publicado: (2020)

Aspirin for Primary Prevention of Cardiovascular Diseases: “WALTZ” with the Evidence
por: Dimitriadis, Kyriakos, et al.
Publicado: (2022)

Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk
por: Elwood, Peter C., et al.
Publicado: (2016)

Aspirin for the Primary Prevention of Cardiovascular Events: A systematic review and meta-analysis comparing patients with and without diabetes
por: Calvin, Andrew D., et al.
Publicado: (2009)

Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China
por: Jiang, Minghuan, et al.
Publicado: (2019)

Aspirin as Primary Prevention of Acute Coronary Heart Disease Events
por: Glasser, Stephen P., et al.
Publicado: (2014)

Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease
por: Gallagher, Hugh, et al.
Publicado: (2022)

Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease
por: Chen, Yinong, et al.
Publicado: (2021)

Challenging the “Divinity” of Aspirin Monotherapy for Secondary Prevention of Cardiovascular Disease
por: Spartalis, Michael, et al.
Publicado: (2023)

Aspirin for Primary Prevention of Cardiovascular Events: Meta-Analysis of Randomized Controlled Trials and Subgroup Analysis by Sex and Diabetes Status
por: Xie, Manling, et al.
Publicado: (2014)

Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis
por: Ma, Hua, et al.
Publicado: (2021)

Budget Impact of Appropriate Low-Dose Aspirin Use for Primary and Secondary Cardiovascular Event Prevention in the Managed Care Setting
por: Carlton, Rashad, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mk6l0mb25r5cc06cmonpjccr8q